Correlation Analysis Between AKR1B10 And Adjuvant Chemotherapy In Breast Cancer

Objective: To investigate the expression of AKR1B10 in breast cancer, and analyze the correlationship between AKR1B10 and therapeutic effectiveness of adjuvant chemotherapy in breast cancer.Methods: We collected 71 patients with breast cancer who received neoadjuvant chemotherapy in the First People's Hospital of Chenzhou from October 1, 2009 to December 30, 2015. 71 paired tissues from the breast cancer patient were collected before and after neoadjuvant chemotherapy. The expression of AKR1B10 in the tissues was determined by immunohistochemistry. The correlation between AKR1B10 expression levels and clinical pathological characters including the therapeutic effectiveness of neoadjuvant chemotherapy were analyzed by SPSS 18.0 software. The MCF-7/AKR1B10 cell with the expression of AKR1B10 was established by gene transfection. The cellular proliferation inhibition rates of MCF-7/AKR1B10 cell and MCF-7/vector cell after treated by different concentrations of Pirarubicin(THP) were measured by MTT.Results:(1) The positive rate of AKR1B10 expression was 90.1% in 71 patients with breast cancer. There were positive correlations between the expression levels of AKR1B10 before chemotherapy and tumor size or lymph node metastasis(p<0.05).(2) The expression level of AKR1B10 was significantly increased after neoadjuvant chemotherapy(p=0.009).(3)There was no correlation between the expression level of AKR1B10 before neoadjuvant chemotherapy and neoadjuvant chemotherapy(p>0.05).(4)The results of Western blot showed that the MCF-7/AKR1B10 cell was constructed successfully. The cell proliferation between MCF-7/AKR1B10 cells with AKR1B10 expression and MCF-7/vector without AKR1B10 was not significantly different after THP treatment.Conclusions:(1) The positive correlation was found between AKR1B10 expression and tumor size, lymph node metastasis in the patients of breast cancer.(2) There was no correlation between the expression level of AKR1B10 before neoadjuvant chemotherapy and therapeutic effectiveness, because AKR1B10 did not affect the effect of THP on the proliferation of breast cancer cells.